These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 23958572

  • 1. Criteria influencing the choice of starting insulin regimen in patients with type 2 diabetes in routine clinical practice: baseline data from the Algerian cohort of the A₁chieve study.
    Malek R, Arbouche Z, Bachaoui M, Zinai S, Dahaoui A, Senoussaoui S, Salah-Mansour A.
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S45-9. PubMed ID: 23958572
    [Abstract] [Full Text] [Related]

  • 2. Initiating or switching to biphasic insulin aspart 30 in type 2 diabetes patients from Algeria: a sub-analysis of the A₁chieve study.
    Lezzar A, Ayad F, Dahaoui A, Salah-Mansour A, Berrouiguet AY.
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S37-44. PubMed ID: 23958570
    [Abstract] [Full Text] [Related]

  • 3. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
    Rys P, Wojciechowski P, Siejka S, Małecki P, Hak L, Malecki MT.
    Int J Clin Pract; 2014 Mar; 68(3):304-13. PubMed ID: 24471814
    [Abstract] [Full Text] [Related]

  • 4. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
    Dieuzeide G, Chuang LM, Almaghamsi A, Zilov A, Chen JW, Lavalle-González FJ.
    Prim Care Diabetes; 2014 Jul; 8(2):111-7. PubMed ID: 23953707
    [Abstract] [Full Text] [Related]

  • 5. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
    Fulcher GR, Christiansen JS, Bantwal G, Polaszewska-Muszynska M, Mersebach H, Andersen TH, Niskanen LK, BOOST: Intensify Premix I Investigators.
    Diabetes Care; 2014 Aug; 37(8):2084-90. PubMed ID: 24812432
    [Abstract] [Full Text] [Related]

  • 6. Safety and effectiveness of insulin analogues in type 2 diabetic patients from Algeria: a sub-analysis of the A₁chieve study.
    Malek R, Arbouche Z, Dahaoui A, Bachaoui M.
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S15-26. PubMed ID: 23958568
    [Abstract] [Full Text] [Related]

  • 7. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
    Linjawi S, Sothiratnam R, Sari R, Andersen H, Hiort LC, Rao P.
    Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
    [Abstract] [Full Text] [Related]

  • 8. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
    Niskanen L, Leiter LA, Franek E, Weng J, Damci T, Muñoz-Torres M, Donnet JP, Endahl L, Skjøth TV, Vaag A.
    Eur J Endocrinol; 2012 Aug; 167(2):287-94. PubMed ID: 22660026
    [Abstract] [Full Text] [Related]

  • 9. Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study.
    Hassan MI, Aamir AH, Miyan Z, Siddiqui LA, Qureshi MS, Shaikh MZ.
    J Pak Med Assoc; 2012 Sep; 62(9):929-36. PubMed ID: 23139978
    [Abstract] [Full Text] [Related]

  • 10. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E, Haluzík M, Canecki Varžić S, Sargin M, Macura S, Zacho J, Christiansen JS.
    Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
    [Abstract] [Full Text] [Related]

  • 11. Exploring insulin analogue safety and effectiveness in a Maghrebian cohort with type 2 diabetes: results from the A₁chieve study.
    Belhadj M, Dahaoui A, Jamoussi H, Farouqi A.
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S4-14. PubMed ID: 23958571
    [Abstract] [Full Text] [Related]

  • 12. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
    Christiansen JS, Niskanen L, Rasmussen S, Johansen T, Fulcher G.
    J Diabetes; 2016 Sep; 8(5):720-8. PubMed ID: 26612062
    [Abstract] [Full Text] [Related]

  • 13. Clinical experience with BIAsp 30: results from the Indonesian cohort of the international A₁chieve study.
    Soewondo P, Pramono RB, Langi YA, Soetedjo NN, Kshanti IA.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S54-9. PubMed ID: 23647720
    [Abstract] [Full Text] [Related]

  • 14. Safety and effectiveness of insulin analogues in Moroccan patients with type 2 diabetes: a sub-analysis of the A₁chieve study.
    Chraibi A, Ajdi F, Belkhadir J, El Ansari N, Marouan F, Farouqi A.
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S27-36. PubMed ID: 23958569
    [Abstract] [Full Text] [Related]

  • 15. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
    Mäkelä JK, Schmüser C, Askonen K, Saukkonen T.
    Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
    [Abstract] [Full Text] [Related]

  • 16. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R, Ajili F, Assaad-Khalil SH, Shinde A, Chen JW, Van den Berg E.
    Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
    [Abstract] [Full Text] [Related]

  • 17. A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study.
    Guo L, Chen L, Chang B, Yang L, Liu Y, Feng B.
    Diabetes Obes Metab; 2018 Dec; 20(12):2740-2747. PubMed ID: 29961975
    [Abstract] [Full Text] [Related]

  • 18. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J, Cohen N, Evans M, Hockey A, Speight J, Whately-Smith C.
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [Abstract] [Full Text] [Related]

  • 19. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
    Taneda S, Hyllested-Winge J, Gall MA, Kaneko S, Hirao K.
    J Diabetes; 2017 Mar; 9(3):243-247. PubMed ID: 27059529
    [Abstract] [Full Text] [Related]

  • 20. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R.
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.